L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes

American Journal of Clinical Nutrition

Volumn 89, Issue 1, 2009, Pages 71-76

  Malaguarnera, Mariano ^a   Vacante, Marco ^a   Avitabile, Teresio ^a   Malaguarnera, Marcella ^a   Cammalleri, Lisa ^a   Motta, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CARNITINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; THIOBARBITURIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPHYLAXIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; BLOOD GLUCOSE; BODY MASS INDEX; CARNITINE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIGLYCERIDES; VITAMIN B COMPLEX;

EID: 58149379405     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2008.26251     Document Type: Article

References (54)

1. Motta M, Bennati E, Capri M, Ferlito L, Malaguarnera M. Diabetes mellitus in the extreme longevity. Exp Gerontol 2008;43:102-5.
2. Fumelli P, Romagnoli F, Carlino G, Fumelli C, Boemi M. Diabetes mellitus and chronic heart failure. Arch Gerontol Geriatr 1996;23:277-81.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Cholesterol Treatment Trialists' Collaborators. Lancet 2005;366:1267-78.
4. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.
5. Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 1995;75:45B-52B.
6. Parthasarathy S, Rankin SM. Role of oxidized low density lipoprotein in atherogenesis. Prog Lipid Res 1992;31:127-43.
7. Boullier A, Bird DA, Chang MK, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 2001;947:214-22.
8. Cominacini L, Pastorino AM, McCarthy A, et al. Determination of lipid hydroperoxides in native low-density lipoprotein by a chemiluminescent flow-injection assay. Biochim Biophys Acta 1993;1165:279-87.
9. De Rijke YB, Verwey HF, Vogelezang CJ, et al. Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atheroscerosis. Clin Chim Acta 1995;243:137-49.
10. Brizzi P, Tonolo G, Carusillo F, Malaguanera M, Maioli M, Musumeci S. Plasma lipid composition and LDL oxidation. Clin Chem Lab Med 2003;41:56-60.
11. Gupta M, Dobashi K, Greene EL, Orak JK, Singh I. Studies on hepatic injury and antioxidant enzyme activities in rat subcellular organelles following in vivo ischemia and reperfusion. Mol Cell Biochem 1997;176:337-47.
12. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;241:215-8.
13. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-6.
14. Motta M, Bennati E, Ferlito L, Malaguarnera M. Diabetes mellitus in the elderly: diagnostic features. Arch Gerontol Geriatr 2006;42:101-6.
15. Motta M, Bennati E, Ferlito L, Passamonte M, Malaguarnera M. Insulin-resistance (IR) in older age. Arch Gerontol Geriatr 2008;46:203-9.
16. Pari L, Latha M. Effect of Cassia auriculata flowers on blood sugar levels, serum and tissue lipids in streptozotocin diabetic rats. Singapore Med J 2002;43:617-21.
17. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-12.
18. Wolff SP. The potential role of oxidative stress in diabetes and ist complications: novel implications for theory and therapy. In: Crabbe MJC, ed. Diabetic complications: scientific and clinical aspects. London, United Kingdom: Churchill Livingstone, 1987:167-221.
19. Motta M, Bennati E, Ferlito L, et al. Cardio-cerebrovascular complications in elderly with diabetes. Arch Gerontol Geriatr 2007;44:261-9.
20. Bonnard C, Durand A, Peyrol S, et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest 2008;118:789-800.
21. Carter AL, Abney TO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol 1995;10(suppl 2):S3-7.
22. Seccombe DW, James L, Hahn P, Jones E. L-Carnitine treatment in the hyperlipidemic rabbit. Metabolism 1987;36:1192-6.
23. Irat AM, Aktan F, Ozansoy G. Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol 2003;55:1389-95.
24. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N. L-Carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 2001;44:235-42.
25. Mitwalli AH, Al-Wakeel JS, Alam A, et al. L-Carnitine supplementation in hemodialysis patients. Saudi J Kidney Dis Transpl 2005;16:17-22.
26. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28:S37-42.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
28. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-6.
29. Holvoet P. Oxidative modification of low-density lipoproteins in atherothrombosis. Acta Cardiol 1998;53:253-60.
30. Sirtori CR, Calabresi L, Ferrara S, et al. L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000;10:247-51.
31. Casciani CU, Caruso U, Cravotto E, et al. Effect of L-carnitine on lipid pattern in haemodialysis. Lancet 1980;316:1309-10.
32. Vacha GM, Giorcelli G, Siliprandi N, Corsi M. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr 1983;38:532-40.
33. Orzali A, Donzelli F, Enzi G, Rubaltelli FF. Effect of carnitine on lipid metabolism in the newborn. I. Carnitine supplementation during total parenteral nutrition in the first 48 hours of life. Biol Neonate 1983;43:186-90.
34. Penn D, Schmidt-Sommerfeld E. Carnitine and carnitine esters in plasma and adipose tissue of chronic uremic patients undergoing hemodialysis. Metabolism 1983;32:806-9.
35. Brown GC, Borutaite V. Nitric oxide, cytochrome c and mitochondria. Biochem Soc Symp 1999;66:17-25.
36. Kremser K, Stangl H, Pahan K, Singh I. Nitric oxide regulates peroxisomal enzyme activities. Eur J Clin Chem Clin Biochem 1995;33:763-74.
37. Binienda ZK, Ali SF. Neuroprotective role of L-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicol Lett 2001;125:67-73.
38. Hongu N, Sachan DS. Caffeine, carnitine and choline supplementation of rats decreases body fat and serum leptin concentration as does exercise. J Nutr 2000;130:152-7.
39. Hongu N, Sachan DS. Carnitine and choline supplementation with exercise alter carnitine profiles, biochemical markers of fat metabolism and serum leptin concentration in healthy women. J Nutr 2003;133:84-9.
40. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
41. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
42. Binienda ZK. Neuroprotective effects of L-carnitine in induced mitochondrial dysfunction. Ann N Y Acad Sci 2003;993:289-95.
43. Kumaran S, Deepak B, Naveen B, Panneerselvam C. Effects of levocarnitine on mitochondrial antioxidant systems and oxidative stress in aged rats. Drugs R D 2003;4:141-7.
44. Ramsay RR, Gandour RD. Selective modulation of carnitine long-chain acyltransferase activities: kinetics, inhibitors, and active sites of COT and CPT-II. Adv Exp Med Biol 1999;466:103-9.
45. Sushamakumari S, Jayadeep A, Kumar JS, Menon VP. Effect of carnitine on malondialdehyde, taurine and glutathione levels in heart of rats subjected to myocardial stress by isoproterenol. Indian J Exp Biol 1989;27:134-7.
46. Yasui F, Matsugo S, Ishibashi M, et al. Effects of chronic acetyl-L-carnitine treatment on brain lipid hydroperoxide level and passive avoidance learning in senescence-accelerated mice. Neurosci Lett 2002;334:177-80.
47. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25:1429-39.
48. Solfrizzi V, Capurso C, Colacicco AM, et al. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis 2006;188:455-61.
49. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr 2008;46:181-90.
50. Malaguarnera M, Di Mauro A, Gargante PM, Rampello L. L-carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. South Med J 2006;99:315-6.
51. Pistone G, Marino A, Leotta C, Dell'Arte S, Finocchiaro G, Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 2003;20:761-7.
52. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.
53. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 1981;25:373-8.
54. Motta M, Bennati E, Ferlito L, Passamonte M, Cardillo E, Malaguarnera M. A review on the actual trends of insulin treatment in elderly with diabetes. Arch Gerontol Geriatr 2008;47:151-61.